COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
|
|
- Buddy May
- 6 years ago
- Views:
Transcription
1 COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY)
2 ANTIPLATELET DRUGS, PCI AND CORONARY SURGERY -ASPIRIN -THIENOPYRIDINE (TICLOPIDINE, CLOPIDOGREL, NEW DRUGS: PRASUGREL) -GpIIb/IIIa INHIBITORS (Abciximab; Eptifibatide;Tirofiban)
3
4
5 ASPIRIN Cyclooxygenase (COX-1) expression (vascular endothelium) COX-1 induces TXA 2 release from stimulated platelets TXA 2 activates TP-receptor on platelet surface membrane, inducing aggregation Aspirin binds to COX-1, inhibiting irreversibly TXA 2 formation
6 ASPIRIN ACTION Following a single 100 mg dose of aspirin, the ability of whole blood to generate TXA recovers in 2 parallel with the appearance of new platelets and achieves pretreatment levels at 8-10 days.
7 ASPIRIN CESSATION ACC/AHA Guidelines: 7-10 DAYS BEFORE ELECTIVE CABG -Prolonged wound closure time -Four-fold increase in early operation for bleeding excess -Increased risk for transfusions
8 ASPIRIN CESSATION STS Recommendation: Cessation of aspirin in purely elective patients without acute coronary syndrome at least 2-3 days before surgery in the expectation that rates of blood transfusion will be reduced
9 NO ASPIRIN CESSATION ACC/AHA Guidelines: Patients who may have an acute coronary syndrome, and where the benefits of interruption may outweigh risks: -UNSTABLE ANGINA -CRITICAL LEFT MAIN CORONARY DISEASE -SEVERE THREE VESSELS CORONARY DISEASE
10 CLOPIDOGREL THIENOPYRIDINE WHICH WORKS THROUGH A NON-COMPETITIVE INHIBITION OF THE PLATELET ADP P2Y 12 RECEPTOR, REDUCING PLATELET AGGREGATION
11
12 CLOPIDOGREL CESSATION
13 CLOPIDOGREL IN HIGH RISK PATIENTS Does clopidogrel cause an increase in bleeding complications and their sequelae? Does withholding clopidogrel expose to an increase in thrombotic complications prior to surgery?
14 CLOPIDOGREL AND URGENT SURGERY Mean increase in blood loss of % A 2-5 times increase in the need for re-exploration Increase in adverse events (allogeneic transfusions) and intubation time NO differences in hospital length of stay NO differences in mortality
15 CLOPIDOGREL CESSATION
16 CLOPIDOGREL CESSATION PCI-CURE STUDY The mean wait for PCI was 6 days The incidence of a myocardial infarction is about 1% lower in patients treated with clopidogrel respect to placebo
17 CLOPIDOGREL CESSATION
18 CLOPIDOGREL CESSATION AHA GUIDELINES Patients requiring urgent coronary arterial bypass grafting should have their clopidogrel omitted for 5-7 days prior to their surgery if their clinical condition allows. The benefits in terms of reduction in peri-operative blood loss, reduced risk of re-exploration and reduction of blood product usage is at the expense of a 1% increase in the risk of MI while awaiting surgery
19 NEW THIENOPYRIDINES
20 POSITIVE RESULTS OF TRITON-TIMI 38 STUDY Compared to Clopidogrel, Prasugrel (60 mg) induces a lower rate of myocardial infarction and stent thrombosis early, and also after 15 months. -
21 NEGATIVE RESULTS OF TRITON-TIMI 38 STUDY Major bleeding after urgent CABG surgery about 7 times greater (2.7 vs 18.8%) -
22 GpIIb/IIIa INHIBITORS EFFECTS ABCIXIMAB: prolonged half-life EPTIFIBATIDE short half-life TIROFIBAN short half-life
23
24 GpIIb/IIIa INHIBITORS CESSATION ABCIXIMAB 12 HOURS EPTIFIBATIDE 2 HOURS TIROFIBAN 2 HOURS
25 OPERATIVE STRATEGIES Off-pump surgery Anti-hemorrhagic drugs Platelet Transfusion
26 OPCABG Is there a real advantage to perform coronary surgery without cardiopulmonary bypass in patients preoperative treated with anti-platelet drugs?
27
28 OPCABG
29 OPCABG
30 OPCABG
31 OPCAB AND ANTI-PLATELET DRUGS -Clopidogrel is associated with an increased risk of peri-operative bleeding even in OPCAB surgery. -The interruption of anti-platelet drugs must follow the same indications as for on-pump surgery
32 ANTI-HEMORRHAGIC DRUGS -APROTININ -SYNTHETIC ANTI-FIBRINOLYTIC DRUGS (Tranexamic acid, E-aminocaproic acid)
33 APROTININ Natural derivative product from the bovine lung, which acts through: -Serine protease inhibition -Antifibrinolytic effect -Preservation of the platelet function during CPB
34 APROTININ
35 APROTININ
36 APROTININ
37 COMPARISON OF TRANEXAMIC ACID AND APROTININ
38 TRANEXAMIC ACID: OUR EXPERIENCE
39 CONCLUSIONS (1) The management of patients treated with anti-platelet drugs requires a thorough balance between the risk of major bleeding, and the risk of ischemic myocardial events.
40 CONCLUSIONS (2) THE ART OF CLINICAL DECISION MAKING HAS NEVER BEEN MORE ESSENTIAL
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationAntiplatelet Therapy and Cardiac Surgery: A Challenge? The use of aspirin and clopidogrel in cardiac surgery
Jeroen De Haes Promotor: Dr. Poortmans Antiplatelet Therapy and Cardiac Surgery: A Challenge? The use of aspirin and clopidogrel in cardiac surgery Overview Indications of DAPT Pharmacology Aspirin P2Y
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD
ASA PLAVIX AND PREOPERATIVE OPTIMIZATION John Hann, MD QUESTIONS: WHICH ANTI-PLATELETS DO YOU STOP AND WHEN? 1. 65 yo M with history of stroke on ASA PreOp eval for cataracts surgery 2. 65 yo M with RCRI
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationClinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt. doi: /01.RES
Clinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt Circ Res. 2007;100:1261-1275 doi: 10.1161/01.RES.0000264509.36234.51 Circulation Research is published
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationPreoperative antithrombotic management: before cardiac surgery. S. Demertzis
Preoperative antithrombotic management: before cardiac surgery S. Demertzis Facts > CABG-related bleeding complications & perioperative acute coronary events are strongly influenced by the management of
More informationMayor lung resection in the presence of anti-platelet therapy. Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne
Mayor lung resection in the presence of anti-platelet therapy Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne THORACIC SURGERY IN THE PRESENCE OF ANTI-PLATELET THERAPY Charybdis: Thrombosis
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationMultiplate analyzer Cut-off-values ADPtest and ASPItest
Multiplate analyzer Cut-off-values ADPtest and ASPItest Cut-off values ADPtest The cut-off values were established in hirudin blood samples. Healthy individuals AUC (U) 1 Patient on ADP receptor antagonist
More informationAcute Coronary Syndromes Compendium
Acute Coronary Syndromes Compendium Circulation Research Compendium on Acute Coronary Syndromes Acute Coronary Syndromes: Pathology, Diagnosis, Genetics, Prevention, and Treatment Mechanisms of Plaque
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationNew data for preventing postoperative hemorrhage with the use of aprotinin
New data for preventing postoperative hemorrhage with the use of aprotinin Nikolaos BAIKOUSSIS MD, MSc, PhD Cardiac Surgeon Ippokrateio General Hospital of Athens No conflict of interest Bleeding
More informationThromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH
Thromboelastograph (TEG ) Utilization in Blood Management Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH TEG Hemostasis System ROTEM Delta Whole blood Hemostasis Analyzer Personalized
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationFigure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE
CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationNewer Antiplatelets. Asha Moorthy, Jain T Kallarakkal, James Kumar P INTRODUCTION
ewer Antiplatelets Asha Moorthy, Jain T Kallarakkal, James Kumar P ITRODUCTIO Many therapeutic drugs have been identified that possess clinically important antiplatelet activity. Platelet inhibition can
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationAntiplatelet therapy is the mainstay of pharmacological
Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationLA TERAPIA ANTIAGGREGANTE PER VIA PARENTERALE
LA TERAPIA ATIAGGREGATE PER VIA PARETERALE Sergio Leonardi, MD, MHS, FESC Cardiovascular Clinical Research Center Fondazione IRCCS Policlinico San Matteo Pavia, Italy 28 March 2015 Induno, BG CI-1 Terapia
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationAntithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France
Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Disclosures Research grants: Astra-Zeneca, Merck, Novartis, Pfizer, sanofi-aventis, Servier, The MedCo Fees
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationRisks of Bleeding and Transfusion January 7, 2018 Henry Green, MD, FACC, FACP
Risks of Bleeding and Transfusion January 7, 2018 Henry Green, MD, FACC, FACP Introduction Antithrombotic drugs are protective in acute coronary syndromes, reduce the risk of embolism in atrial fibrillation,
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationKeeping Coronary Stents Patent in Patients Priya Kumar, M.D. University of North Carolina, Chapel Hill, NC
Session: L232 Session: L432 Keeping Coronary Stents Patent in Patients Priya Kumar, M.D. University of North Carolina, Chapel Hill, NC Disclosures: This presenter has no financial relationships with commercial
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationA patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationDifferences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific?
Differences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific? DR.O.SAI SATISH PROFESSOR DEPARTMENT OF CARDIOLOGY NIMS Death is inevitable but Premature death is not Sir Richard Doll Topic outline
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More information